Grant C. Bogle - 17 Mar 2022 Form 4 Insider Report for Epizyme, Inc.

Role
President and Chief Executive Officer, Director
Signature
/s/ John Weidenbruch, attorney-in-fact
Issuer symbol
N/A
Transactions as of
17 Mar 2022
Net transactions value
$0
Form type
4
Filing time
21 Mar 2022, 18:06:45 UTC
Previous filing
04 Feb 2022
Next filing
11 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EPZM Stock Option (Right to Buy) Award $0 +800,000 $0.000000 800,000 17 Mar 2022 Common Stock 800,000 $1.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on March 17, 2022 pursuant to the Company's 2013 Stock Incentive Plan with respect to 800,000 shares of Common Stock, with 25% vesting on March 17, 2023 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

Remarks:

President and Chief Executive Officer